Caris Life Sciences, Inc.
CAI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 6/30/2024 | |
|---|---|---|---|---|
| Market Cap | $8,533,497 | $7,172,823 | $7,134,089 | $7,134,089 |
| - Cash | $753,221 | $718,934 | $31,201 | $0 |
| + Debt | $426,738 | $418,980 | $419,826 | $0 |
| Enterprise Value | $8,207,014 | $6,872,869 | $7,522,714 | $7,134,089 |
| Revenue | $216,833 | $181,398 | $120,915 | $100,049 |
| % Growth | 19.5% | 50% | 20.9% | – |
| Gross Profit | $147,506 | $113,685 | $57,063 | $37,554 |
| % Margin | 68% | 62.7% | 47.2% | 37.5% |
| EBITDA | $42,702 | -$46,173 | -$82,754 | -$40,902 |
| % Margin | 19.7% | -25.5% | -68.4% | -40.9% |
| Net Income | $24,325 | -$71,790 | -$102,581 | -$66,186 |
| % Margin | 11.2% | -39.6% | -84.8% | -66.2% |
| EPS Diluted | 0.082 | -1.87 | -0.4 | -0.35 |
| % Growth | 104.4% | -367.5% | -14.3% | – |
| Operating Cash Flow | $62,425 | $7,288 | -$31,338 | -$62,926 |
| Capital Expenditures | -$7,095 | -$1,386 | -$2,689 | -$2,588 |
| Free Cash Flow | $55,330 | $5,902 | -$34,027 | -$65,514 |